Your session is about to expire
← Back to Search
INCB054707 for Prurigo Nodularis
Study Summary
This trial will study whether a new medication is effective and safe for treating prurigo nodularis, a skin condition.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 2 trial • 10 Patients • NCT03569371Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am not pregnant, considering pregnancy, or breastfeeding.I have a history of blood clotting issues, heart rhythm problems, or serious infections.My previous treatments for PN were not effective or caused side effects.I have more than 20 itchy spots on at least 2 different parts of my body.I am currently taking medication that causes itching.I have been diagnosed with peripheral neuropathy for at least 3 months.You have 20 or more lumps in at least 2 different parts of your body during the screening and on Day 1.I have an active, latent, or untreated TB infection.I am known to have HIV, Hepatitis B, or Hepatitis C.I have a condition causing chronic itching without a known skin disease.I have long-term itching not caused by nerve damage.My previous nerve pain treatment didn't work or caused side effects.Your lab test results are not within the specified normal ranges outlined in the study.
- Group 1: INCB054707 Dose A
- Group 2: INCB054707 Dose B
- Group 3: INCB054707 Dose C
- Group 4: Placebo followed by INCB054707 Dose B or C
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could you please elaborate on the risks associated with INCB054707?
"INCB054707 falls into Phase 2 of clinical trials. While there is data suggesting it is safe, none of the trials have yet shown that it is an effective medication."
How many patients are being monitored in this clinical trial?
"One hundred and forty participants who satisfy the prerequisites are needed for this experiment. Those taking part can do so from various locations, such as Investigative Site US024 in Phoenix, Arizona or Investigative Site US018 in Dallas, Texas."
In how many different countries is this trial taking place?
"28 clinical sites are enrolling patients for this trial, such as Investigative Site US024 in Phoenix, Investigative Site US018 in Dallas, and Investigative Site US005 in Austin. There are also enrolment locations."
Are new participants being sought for this experiment?
"The trial you are inquiring about is, as of now, searching for patients to participate. This information was updated as recently as November 15th, 2021 on clinicaltrials.gov. The trial was originally posted almost a year ago on November 4th, 2020."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger